Cargando…
The Prognostic Value of Lymph Node Involvement after Neoadjuvant Chemotherapy Is Different among Breast Cancer Subtypes
SIMPLE SUMMARY: Little is known about whether residual axillary disease after neoadjuvant chemotherapy carries a different prognostic value by breast cancer subtype. We retrospectively evaluated the axillary involvement (0, 1 to 3 positive nodes, ≥4 positive nodes) on surgical specimens from a cohor...
Autores principales: | Laot, Lucie, Laas, Enora, Girard, Noemie, Dumas, Elise, Daoud, Eric, Grandal, Beatriz, Pierga, Jean-Yves, Coussy, Florence, Kirova, Youlia, El-Alam, Elsy, Bataillon, Guillaume, Lae, Marick, Llouquet, Florence, Reyal, Fabien, Hamy, Anne-Sophie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825348/ https://www.ncbi.nlm.nih.gov/pubmed/33418983 http://dx.doi.org/10.3390/cancers13020171 |
Ejemplares similares
-
No Impact of Smoking Status on Breast Cancer Tumor Infiltrating Lymphocytes, Response to Neoadjuvant Chemotherapy and Prognosis
por: Simon, Vanille, et al.
Publicado: (2020) -
Impact of BRCA Mutation Status on Tumor Infiltrating Lymphocytes (TILs), Response to Treatment, and Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
por: Grandal, Beatriz, et al.
Publicado: (2020) -
HER2-Positive Breast Cancer Patients with Pre-Treatment Axillary Involvement or Postmenopausal Status Benefit from Neoadjuvant Rather than Adjuvant Chemotherapy Plus Trastuzumab Regimens
por: Laas, Enora, et al.
Publicado: (2021) -
PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy
por: Grandal, Beatriz, et al.
Publicado: (2021) -
The Presence of an In Situ Component on Pre-Treatment Biopsy Is Not Associated with Response to Neoadjuvant Chemotherapy for Breast Cancer
por: Labrosse, Julie, et al.
Publicado: (2021)